Why the study?
Do NSAIDs and COX-2 inhibitors increase cardiovascular risks in patients requiring pain and inflammation relief?
Do NSAIDs and COX-2 inhibitors increase cardiovascular risks in patients requiring pain and inflammation relief?
Answers are grounded in this paper and cite their sources.
Physicians must carefully weigh individual gastrointestinal and cardiovascular risk profiles when selecting NSAIDs or COX-2 inhibitors due to their varying prothrombotic and hypertensive risks.
Nonsteroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase (COX-2) inhibitors, or "coxibs," are used for a number of disease conditions for relief of pain and inflammation. Currently available data suggest concern for prothrombotic risk with coxibs and some NSAIDs, and the magnitude of risk may vary with individual agents. NSAIDs and coxibs also increase blood pressure, worsen hypertension control, and may precipitate heart failure, with important differences among agents. Physicians should consider patterns of risk and benefit in selecting the most appropriate agent for individual patients based on the individual gastrointestinal and cardiovascular risk profile.
No takes yet. Share an insight, caveat, or question.
Debabrata Mukherjee (2008) conducted a review in Pain and inflammation. NSAIDs and COX-2 inhibitors was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: